TRCT
ALT icon

Tower Research Capital (TRC)’s Altimmune ALT Stock Holding History

Tower Research Capital (TRC)’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.6K Buy
14,488
+6,299
+77% +$26.7K ﹤0.01% 2844
2025
Q4 		$29.6K Sell
8,189
-1,232
-13% -$5.37K ﹤0.01% 2817
2025
Q3 		$35.5K Sell
9,421
-5,535
-37% -$21.4K ﹤0.01% 2789
2025
Q2 		$57.9K Buy
14,956
+10,490
+235% +$56.8K ﹤0.01% 2840
2025
Q1 		$22.3K Sell
4,466
-21,277
-83% -$135K ﹤0.01% 2853
2024
Q4 		$186K Sell
25,743
-1,217
-5% -$9.3K ﹤0.01% 1772
2024
Q3 		$166K Buy
26,960
+6,369
+31% +$43.1K ﹤0.01% 1792
2024
Q2 		$137K Buy
20,591
+9,906
+93% +$73.1K ﹤0.01% 2357
2024
Q1 		$109K Buy
10,685
+93
+0.9% +$946 ﹤0.01% 1784
2023
Q4 		$119K Buy
10,592
+4,427
+72% +$18.5K ﹤0.01% 2514
2023
Q3 		$16K Sell
6,165
-20,592
-77% -$59.1K ﹤0.01% 3579
2023
Q2 		$94.5K Buy
26,757
+6,664
+33% +$29.9K ﹤0.01% 2062
2023
Q1 		$85K Sell
20,093
-9,214
-31% -$109K ﹤0.01% 2010
2022
Q4 		$482K Buy
29,307
+171
+0.6% +$1.92K 0.02% 728
2022
Q3 		$373K Buy
29,136
+23,098
+383% +$341K 0.01% 1375
2022
Q2 		$71K Sell
6,038
-11,787
-66% -$72.7K ﹤0.01% 2564
2022
Q1 		$108K Sell
17,825
-6,855
-28% -$50.5K ﹤0.01% 2140
2021
Q4 		$226K Buy
24,680
+19,544
+381% +$208K ﹤0.01% 1661
2021
Q3 		$58K Sell
5,136
-17,799
-78% -$216K ﹤0.01% 2820
2021
Q2 		$226K Buy
22,935
+19,385
+546% +$265K 0.01% 1827
2021
Q1 		$51K Buy
3,550
+2,418
+214% +$39.1K ﹤0.01% 3101
2020
Q4 		$13K Sell
1,132
-409
-27% -$4.82K ﹤0.01% 4126
2020
Q3 		$20K Buy
1,541
+1,248
+426% +$24.9K ﹤0.01% 3861
2020
Q2 		$3K Buy
+293
New +$1.61K ﹤0.01% 4387
2017
Q3 		– Sell
-452
Closed -$44K – 3749
2017
Q2 		$44K Buy
+452
New +$75.1K 0.01% 805
2016
Q2 		– Sell
-7
Closed -$4K – 4387
2016
Q1 		$4K Buy
+7
New +$3.58K ﹤0.01% 2843
2015
Q4 		– Hold
0
– – – 4423
2015
Q3 		– Sell
-1
Closed -$474 – 3941
2015
Q2 		$1K Sell
1
-1
-50% -$505 ﹤0.01% 3952
2015
Q1 		$1K Buy
2
+1
+100% +$498 ﹤0.01% 4004
2014
Q4 		$0 Hold
1
– – ﹤0.01% 3965
2014
Q3 		$0 Sell
1
-1
-50% -$523 ﹤0.01% 4380
2014
Q2 		$1K Hold
2
– – ﹤0.01% 3609
2014
Q1 		$1K Sell
2
-5
-71% -$2.92K ﹤0.01% 4099
2013
Q4 		$4K Buy
7
+5
+250% +$2.98K ﹤0.01% 3645
2013
Q3 		$1K Buy
+2
New +$1.15K ﹤0.01% 4264
2013
Q2 		– Hold
0
– – – 3902

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Tower Research Capital (TRC)'s ALT Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Altimmune (ALT) stake by 77% in Q1 2026, buying an estimated $26.7K and bringing the position to 14,488 shares worth $44.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2844.

Tower Research Capital (TRC) first reported a position in ALT in Q3 2013 and has held it in 34 quarters since. The position peaked at $482K in Q4 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • Tower Research Capital (TRC) held 14,488 shares of Altimmune worth $44.6K as of Q1 2026.
  • Tower Research Capital (TRC) bought 6,299 Altimmune shares in Q1 2026, an estimated $26.7K.
  • Altimmune made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2844 holding.
  • Tower Research Capital (TRC) first reported a position in Altimmune in Q3 2013 and has held it in 34 quarters since.
  • Tower Research Capital (TRC)'s Altimmune position peaked at $482K in Q4 2022.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.